AstraZeneca throws down the gauntlet with a PhIII victory in head-to-head PARP war with Tesaro
AstraZeneca has posted another success in its campaign to expand the use of its PARP inhibitor Lynparza (olaparib).
In what has become a head-to-head showdown with Tesaro, which has a rival PARP under review at the FDA, AstraZeneca today heralded a top-line success for Lynparza in a Phase III study of HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations.
Like Tesaro, AstraZeneca’s pivotal study focused on a comparison with physician’s choice of chemotherapies, with Lynparza coming out ahead on progression-free survival.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.